Literature DB >> 18636227

Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.

Sargis Khoobiar1, Nicolai Mejevoi, Khalil Kaid, Catalin Boiangiu, Sampoornima Setty, Anjum Tanwir, Khaula Khalid, Marc Cohen.   

Abstract

BACKGROUND: Enoxaparin use in PCI has been investigated, however its role in primary PCI is less known.
OBJECTIVE: To evaluate the role of combination IV + SC enoxaparin in primary PCI in STEMI.
METHODS: 83 consecutive patients with STEMI who underwent primary PCI between January 1, 2005 and January 15, 2008 were included. Anticoagulation was based on our institution's STEMI protocol; either IV + SC enoxaparin, or IV unfractionated heparin (UFH). Clinical endpoints included MACE, bleeding and net adverse cardiac events (NACE).
RESULTS: 45 patients received UFH and 37 received IV + SC enoxaparin. There was no difference in the rate of mortality, MACE, or NACE. There was a trend toward more TIMI major and GUSTO moderate and severe bleeding in the UFH group.
CONCLUSIONS: Application of IV + SC enoxaparin strategy for primary PCI in STEMI appears both safe and efficacious. A prospective randomized trial will be necessary to evaluate the safety and efficacy more thoroughly.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18636227     DOI: 10.1007/s11239-008-0258-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  17 in total

1.  A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.

Authors:  Robert C Welsh; Phillip Gordon; Cynthia M Westerhout; Christopher E Buller; Blair O'Neill; Paul W Armstrong
Journal:  Catheter Cardiovasc Interv       Date:  2007-09       Impact factor: 2.692

2.  Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.

Authors:  Christopher E Buller; Gordon E Pate; Paul W Armstrong; Blair J O'Neill; John G Webb; Richard Gallo; Robert C Welsh
Journal:  Can J Cardiol       Date:  2006-05-01       Impact factor: 5.223

3.  Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25).

Authors:  Elliott M Antman; David A Morrow; Carolyn H McCabe; Frank Jiang; Harvey D White; Keith A A Fox; Divakar Sharma; Paul Chew; Eugene Braunwald
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.

Authors:  E G Bovill; M L Terrin; D C Stump; A D Berke; M Frederick; D Collen; F Feit; J M Gore; L D Hillis; C T Lambrew
Journal:  Ann Intern Med       Date:  1991-08-15       Impact factor: 25.391

6.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Authors:  James J Ferguson; Robert M Califf; Elliott M Antman; Marc Cohen; Cindy L Grines; Shaun Goodman; Dean J Kereiakes; Anatoly Langer; Kenneth W Mahaffey; Christopher C Nessel; Paul W Armstrong; Alvaro Avezum; Phil Aylward; Richard C Becker; Luigi Biasucci; Steven Borzak; Jacques Col; Marty J Frey; Ed Fry; Dietrich C Gulba; Sema Guneri; Enrique Gurfinkel; Robert Harrington; Judith S Hochman; Neal S Kleiman; Martin B Leon; Jose Luis Lopez-Sendon; Carl J Pepine; Witold Ruzyllo; Steven R Steinhubl; Paul S Teirstein; Luis Toro-Figueroa; Harvey White
Journal:  JAMA       Date:  2004-07-07       Impact factor: 56.272

7.  Bivalirudin during primary PCI in acute myocardial infarction.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

8.  Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.

Authors:  C Michael Gibson; Sabina A Murphy; Gilles Montalescot; David A Morrow; Diego Ardissino; Marc Cohen; Dietrich C Gulba; Oscar H Kracoff; Basil S Lewis; Nathan Roguin; Elliott M Antman; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2007-05-25       Impact factor: 24.094

9.  Prognostic value of a coronary artery jeopardy score.

Authors:  R M Califf; H R Phillips; M C Hindman; D B Mark; K L Lee; V S Behar; R A Johnson; D B Pryor; R A Rosati; G S Wagner
Journal:  J Am Coll Cardiol       Date:  1985-05       Impact factor: 24.094

Review 10.  Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.

Authors:  Sabina A Murphy; Charles Michael Gibson; David A Morrow; Frans Van de Werf; Ian B Menown; Shaun G Goodman; Kenneth W Mahaffey; Marc Cohen; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Journal:  Eur Heart J       Date:  2007-06-28       Impact factor: 29.983

View more
  3 in total

1.  The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study).

Authors:  Jack L Martin; Edward T A Fry; Todd Martin; Trevor H Atherley; Seth S Martin; Marvin J Slepian
Journal:  J Thromb Thrombolysis       Date:  2009-03-17       Impact factor: 2.300

Review 2.  Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention.

Authors:  Sadegh Ali-Hassan-Sayegh; Seyed Jalil Mirhosseini; Azadeh Shahidzadeh; Parisa Mahdavi; Mahbube Tahernejad; Fatemeh Haddad; Mohammad Reza Lotfaliani; Anton Sabashnikov; Aron-Frederik Popov
Journal:  Indian Heart J       Date:  2016-01-26

Review 3.  Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.

Authors:  Johanne Silvain; Farzin Beygui; Olivier Barthélémy; Charles Pollack; Marc Cohen; Uwe Zeymer; Kurt Huber; Patrick Goldstein; Guillaume Cayla; Jean-Philippe Collet; Eric Vicaut; Gilles Montalescot
Journal:  BMJ       Date:  2012-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.